Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice

Passive immunization with anti-tau monoclonal antibodies has been shown by several laboratories to reduce age-dependent tau pathology and neurodegeneration in mutant tau transgenic mice. These studies have used repeated high weekly doses of various tau antibodies administered systemically for several months and have reported reduced tau pathology of ∼40–50% in various brain regions. Here we show that direct intrahippocampal administration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S tau transgenic mice results in high and durable antibody expression, primarily in neurons. Hippocampal antibody levels achieved after AAV delivery were ∼50-fold more than those reported following repeated systemic administration. In contrast to systemic passive immunization, we observed markedly reduced (≥80–90%) hippocampal insoluble pathological tau species and neurofibrillary tangles following a single dose of AAV-vectored PHF1 compared with mice treated with an AAV-IgG control vector. Moreover, the hippocampal atrophy observed in untreated P301S mice was fully rescued by treatment with the AAV-vectored PHF1 antibody. Vectored passive immunotherapy with an anti-tau monoclonal antibody may represent a viable therapeutic strategy for treating or preventing such tauopathies as frontotemporal dementia, progressive supranuclear palsy, or Alzheimer's disease. SIGNIFICANCE STATEMENT We have used an adeno-associated viral (AAV) vector to deliver the genes encoding an anti-phospho-tau monoclonal antibody, PHF1, directly to the brain of mice that develop neurodegeneration due to a tau mutation that causes frontotemporal dementia (FTD). When administered systemically, PHF1 has been shown to modestly reduce tau pathology and neurodegeneration. Since such antibodies do not readily cross the blood–brain barrier, we used an AAV vector to deliver antibody directly to the hippocampus and observed much higher antibody levels and a much greater reduction in tau pathology. Using AAV vectors to deliver antibodies like PHF1 directly to brain may constitute a novel approach to treating various neurodegenerative disorders, such as FTD and Alzheimer's disease.

[1]  D. Holtzman,et al.  Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models , 2016, Neurobiology of Aging.

[2]  H. Levine,et al.  Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis , 2016, The Journal of Neuroscience.

[3]  Sripriya Ravindra Kumar,et al.  Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain , 2015, Nature Biotechnology.

[4]  E. Sigurdsson.  Tau Immunotherapy , 2015, Neurodegenerative Diseases.

[5]  J. Renger,et al.  Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells , 2015, The Journal of Neuroscience.

[6]  P. Davies,et al.  Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies , 2015, PloS one.

[7]  S. Paul,et al.  Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody , 2015, Scientific Reports.

[8]  E. Sigurdsson,et al.  Tau immunotherapy for Alzheimer's disease. , 2015, Trends in molecular medicine.

[9]  J. Trojanowski,et al.  Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models , 2015, PloS one.

[10]  Keith A. Johnson,et al.  Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging , 2015, Neuropathology and applied neurobiology.

[11]  D. Holtzman,et al.  Anti-tau antibody reduces insoluble tau and decreases brain atrophy , 2015, Annals of clinical and translational neurology.

[12]  B. Hyman,et al.  Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer’s disease , 2014, Acta neuropathologica communications.

[13]  L. Collin,et al.  Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. , 2014, Brain : a journal of neurology.

[14]  Zeshan Ahmed,et al.  A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity , 2014, Acta Neuropathologica.

[15]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[16]  Gabriel Gold,et al.  Alzheimer disease therapy—moving from amyloid-β to tau , 2013, Nature Reviews Neurology.

[17]  E. Sigurdsson,et al.  Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance* , 2013, The Journal of Biological Chemistry.

[18]  E. Sigurdsson,et al.  Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology* , 2013, The Journal of Biological Chemistry.

[19]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo , 2013 .

[20]  P. Davies,et al.  Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity , 2013, PloS one.

[21]  U. Sengupta,et al.  Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau , 2012, Scientific Reports.

[22]  K. Purpura,et al.  Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. , 2012, Human gene therapy methods.

[23]  E. Mandelkow,et al.  Biochemistry and cell biology of tau protein in neurofibrillary degeneration. , 2012, Cold Spring Harbor perspectives in medicine.

[24]  U. Sengupta,et al.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  A. Ittner,et al.  Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice , 2011, PloS one.

[26]  P. Davies,et al.  Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.

[27]  S. Paul.  Therapeutic Antibodies for Brain Disorders , 2011, Science Translational Medicine.

[28]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.

[29]  M. Glucksman,et al.  Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[30]  D. Quartermain,et al.  Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model , 2010, The Journal of Neuroscience.

[31]  M. Sandberg,et al.  AAV-Mediated Gene Delivery in Adult GM1-Gangliosidosis Mice Corrects Lysosomal Storage in CNS and Improves Survival , 2010, PloS one.

[32]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[33]  D. Yin,et al.  Efficient gene therapy-based method for the delivery of therapeutics to primate cortex , 2009, Proceedings of the National Academy of Sciences.

[34]  E. Mandelkow,et al.  The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. , 2008, Biochemistry.

[35]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Ronald L Klein,et al.  Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  Hirotaka Yoshida,et al.  Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein , 2002, The Journal of Neuroscience.

[38]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[39]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[40]  A. Hyman,et al.  Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. , 1992, Molecular biology of the cell.

[41]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[42]  P. Davies,et al.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Vite,et al.  Clinical Improvement of Alpha-mannosidosis Cat Following a Single Cisterna Magna Infusion of AAV1. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  Pavel Osten,et al.  Stereotaxic gene delivery in the rodent brain , 2007, Nature Protocols.

[45]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[46]  I. Grundke‐Iqbal,et al.  Neurofibrillary pathology leads to synaptic loss and not the other way around in Alzheimer disease. , 2002, Journal of Alzheimer's disease : JAD.